Linezolid (Zyvox), a novel antimicrobial agent, has been approved by the U
The Zyvox Annual Appraisal of Potency and Spectrum Program has completed its fifth year of monitoring for emerging resistance to linezolid and other Gram-positive active agents
Podiatry and Chiropody Clinics in Dublin
Abstract
Its spectrum of in vitro and in vivo activity includes staphylococci, streptococci
The safety and efficacy of ZYVOX formulations given for longer than 28days have not been evaluated in controlled clinical trials
Linezolid: Spectrum of in Vitro Activity
Linezolid (lin ayz' oh lid) is a synthetic antibiotic that belongs to the oxazolidinone class
Linezolid is a member of the oxazolidinone class, a new group of antibiotics
Linezolid is extensively absorbed following oral administration and has an absolute bioavailability of approximately 100%
Linezolid (Monograph) Brand name: Zyvox
Venous blood samples were drawn just before the next administration to assess trough plasma concentration (C min) and 30 min after a 1-h intravenous infusion or 2 h after oral administration to assess peak plasma concentration (C max)
The history of linezolid surveillance programmes began several years before product launch with a series of in vitro susceptibility testing studies, including the Zyvox® Appraisal of Potency and Spectrum (ZAAPS) international studies that were initiated before the US FDA release of this product
Linezolid resistance is based on mutations in several 23S rRNA positions, including conserved nucleotides at the antibiotic binding pocket and other nucleotides, and the mutation Gly2576Thr is the most frequent one
K
aureus is the risk of poor outcomes with a narrower spectrum of empiric therapy in severely ill patients if other pathogens are involved